Retatrutide, a novel dual agonist of the GLP-1 target and glucose-dependent secreted polypeptide (GIP) target, is showing promising data in early clinical trials . Current examination indicates that https://mypresspage.com/story6465065/retatrutide-emerging-investigations-and-projected-clinical-uses